All Oncology News

The FDA clears maintenance lurbinectedin combination in lung cancer, T-DxD sBLA in HER2-positive breast cancer is accepted for review, and more.

A mogamulizumab-based combination led to complete remission in a patient with CAR-positive T-cell lymphoma with CCR4 overexpression.

Here is your Q4 2025 preview spotlighting 10 FDA decisions to watch, including upcoming PDUFAs for belantamab mafodotin, revumenib, sevabertinib, and more.

Multiple myeloma and non-Hodgkin lymphoma emerge as key hematology topics ahead of ESMO 2025, followed by MPNs and T-cell lymphoma.

Breast cancer experts vote on their most anticipated abstracts on social media ahead of the 2025 ESMO Congress.

The addition of molecular breast imaging to a 3D mammogram more than doubled the ability to find cancer in dense tissue, according to Mayo Clinic investigators.

Early objective responses have been shown with JNJ-1900 plus immune checkpoint inhibitors for recurrent/metastatic HNSCC.

Paxalisib plus pembrolizumab and chemotherapy led to an 86% reduction in tumor burden in a patient with metastatic triple-negative breast cancer.

A real-world analysis shows avelumab plus axitinib is safe and effective in advanced RCC.

GPC3 has the potential to be targeted in patients with HCC with reduced off-target toxicities compared with other targeted agents.

Here is your guide to all therapeutic options that were approved by the FDA in September 2025 spanning tumor types.

The FDA approved lurbinectedin plus atezolizumab as first-line maintenance for ES-SCLC that has not progressed after frontline induction therapy.

Oncology experts and AI advocates discuss insights about how AI can help manage tasks, keep up with evolving treatment practices, and improve patient care.

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in September 2025.

Five new faculty members have joined the Roswell Park Care Network, with St. Joseph’s Health in Syracuse to begin thoracic surgery services.

The addition of the PD-1 inhibitor to platinum-based chemotherapy demonstrated proof of concept for the use of chemoimmunotherapy in patients with PSCC.

AMXT 1501 plus difluoromethylornithine has received orphan drug designation from the FDA in patients with neuroblastoma.

Four experts share their perspectives on the potential challenges and future directions for AI integration in the field of oncology.

Ahead of the 2025 ESMO Congress, OncLive spoke with experts in lung cancer care to preview the most anticipated meeting abstracts.

Significantly longer recurrence-free survival has been demonstrated with neoadjuvant daromun vs surgery alone in patients with locally advanced melanoma.

DFMO shows promise in reducing metastasis in osteosarcoma and Ewing sarcoma, with phase 2 trials underway to test its role as maintenance therapy.

Samir Parekh, MBBS, discusses monitoring rare CAR T-cell complications, anti-CCR4 therapy, and future research to improve safety and prevent secondary cancers.

In case you missed any, below is a recap of every OncLive On Air episode that aired in September 2025.

This year’s ASTRO program highlights research and expert discussions from UCSF Radiation Oncology and the Helen Diller Family Comprehensive Cancer Center.

ETX-636, a selective PI3Kα inhibitor, has received FDA fast track designation for PIK3CA-mutant, HR-positive, HER2-negative advanced breast cancer.

The FDA accepted an sBLA seeking the approval of neoadjuvant T-DXd followed by THP for the management of high-risk, HER2-positive breast cancer.

ENPP3 offers a potentially attractive treatment target in patients with clear cell RCC.

Katie Goodman, RN, BSN, discusses the ways in which artificial intelligence can help speed up the pace of clinical trial accrual

Experts in the gynecologic cancer landscape highlight their most anticipated presentations ahead of the 2025 ESMO Congress.

The FDA approved Enoby and Xtrenbo, denosumab biosimilars referencing Prolia and Xgeva, respectively.